Hannoun-Levi Jean-Michel, Castelli Joël, Plesu Adrien, Courdi Adel, Raoust Ines, Lallement Michel, Flipo Bernard, Ettore Francette, Chapelier Claire, Follana Philippe, Ferrero Jean-Marc, Figl Andréa
Department of Radiation Therapy, Antoine Lacassagne Cancer Center, Nice, France.
Brachytherapy. 2011 May-Jun;10(3):171-7. doi: 10.1016/j.brachy.2010.05.004. Epub 2010 Aug 4.
To assess early clinical results and evaluate patient satisfaction in case of second conservative treatment (2nd CT) combining lumpectomy plus high-dose rate (HDR) interstitial brachytherapy for patients (pts) presenting with ipsilateral breast cancer recurrence (IBCR).
From June 2005 to July 2009, 42 pts presenting with an IBCR underwent a second lumpectomy with intraoperative implantation of plastic tubes in the tumor bed. After performing the dose distribution analysis on the postimplant CT scan, a total dose of 34 Gy in 10 fractions over 5 consecutive days was delivered. Toxicity evaluation was based on the Common Terminology Criteria for Adverse Events v3.0 criteria. Applying a visual analogic scale (VAS) analysis, patient satisfaction regarding cosmetic result and 2nd CT possibility was performed after the end of brachytherapy.
Median followup was 21 months (range, 6-50 months) and median age at the time of local recurrence was 65 years (range, 30-85 years). Median delay between primary and recurrence was 11 years (range, 1-35 years). Median recurrence tumor size was 12 mm (range, 2-30 mm). Median number of plastic tubes and planes were nine (range, 5-12) and two (range, 1-3), respectively. Median clinical target volume was 68 cc (range, 31.2-146 cc). Second local control rate was 97%. Twenty-two pts (60%) developed complications. Cutaneous and subcutaneous fibrosis was the most frequent side effect. Median VAS satisfaction score regarding cosmetic result was 7 of 10 (range, 4-9), whereas median VAS satisfaction score for 2nd CT was 10 of 10 (range, 8-10).
A 2nd CT for IBCR using high-dose rate brachytherapy seems feasible with encouraging results in terms of second local control with an acceptable toxicity. Patient satisfaction regarding the possibility of second breast preservation should be considered.
评估对同侧乳腺癌复发(IBCR)患者进行保乳手术加近距离高剂量率(HDR)间质内照射治疗的二次保守治疗(2nd CT)的早期临床结果,并评价患者满意度。
2005年6月至2009年7月,42例IBCR患者接受了二次保乳手术,术中在瘤床植入塑料导管。在植入后CT扫描上进行剂量分布分析后,连续5天分10次给予总剂量34 Gy。毒性评估基于不良事件通用术语标准v3.0标准。采用视觉模拟量表(VAS)分析,在近距离放疗结束后对患者的美容效果满意度和二次保守治疗的可能性进行评估。
中位随访时间为21个月(范围6 - 50个月),局部复发时的中位年龄为65岁(范围30 - 85岁)。初次发病与复发之间的中位间隔时间为11年(范围1 - 35年)。复发肿瘤大小的中位数为12 mm(范围2 - 30 mm)。塑料导管和层面的中位数分别为9个(范围5 - 12个)和2个(范围1 - 3个)。临床靶体积的中位数为68 cc(范围31.2 - 146 cc)。二次局部控制率为97%。22例患者(60%)出现并发症。皮肤和皮下纤维化是最常见的副作用。美容效果的VAS满意度评分中位数为10分中的7分(范围4 - 9分),而二次保守治疗的VAS满意度评分中位数为10分中的10分(范围8 - 10分)。
对IBCR患者使用高剂量率近距离放疗进行二次保守治疗似乎可行,在二次局部控制方面取得了令人鼓舞的结果,且毒性可接受。应考虑患者对二次保乳可能性的满意度。